The ANTICOV clinical trial responds to the urgent need to identify treatments that can be used to treat mild and moderate cases of COVID-19 early and prevent spikes in hospitalizations that could overwhelm fragile and already overburdened health systems in low-resource settings.
ANTICOV aims to enrol up to 3,000 participants. The trial was launched in September 2020 in 13 countries by the ANTICOV consortium. The consortium currently includes 27 prominent global research and development organizations, coordinated by the Drugs for Neglected Diseases initiative (DNDi).
One of the largest multi-country trials focusing exclusively on mild and moderate cases of COVID-19, ANTICOV helps address the relative neglect of clinical research during the COVID-19 pandemic in Africa, Asia, and Latin America. ANTICOV employs an innovative ‘adaptive platform’ trial design which allows the consortium to rapidly add or remove treatments as evidence emerges.
